 Chembio Diagnostics Incs NASDAQ: CEMI said that on December 1, it received an FDA notice for additional data related to Clinical Laboratory Improvement Amendment CLIA waiver submission for the DPP HIV-Syphilis test system. In the SEC filing, the Company notes that seeking additional data will extend, for a currently undeterminable period, the process for seeking a CLIA waiver for the DPP HIV-Syphilis test system. 